From GlobeNewswire: 2025-03-27 07:00:00

Acumen Pharmaceuticals, Inc. completed enrollment for the ALTITUDE-AD Phase 2 study to investigate sabirnetug (ACU193) for early Alzheimer’s disease, anticipating topline results in late 2026. The Phase 1 study results for a subcutaneous formulation support further development. The company has $231.5 million in cash and marketable securities as of Dec. 31, 2024, supporting activities into the first half of 2027. A conference call and webcast will be held today at 8:00 a.m. ET.

In recent months, Acumen Pharmaceuticals announced Phase 1 topline results for sabirnetug, demonstrating target engagement and reduction in amyloid plaques. Enrollment for the Phase 2 study, ALTITUDE-AD, is complete, with 542 individuals enrolled to evaluate sabirnetug for early Alzheimer’s disease. Topline results are expected in late 2026. The company’s financial results for 2024 show $231.5 million in cash, with increased R&D and G&A expenses.

The Phase 1 study for a subcutaneous administration of sabirnetug showed promising results, with no safety signals identified. The Phase 2 ALTITUDE-AD study is designed to evaluate the efficacy and safety of sabirnetug in early AD patients, with topline results anticipated in late 2026. The study will assess various AD biomarkers and safety measures, with an open-label extension for participants.

Acumen Pharmaceuticals will host a conference call and webcast today at 8:00 a.m. ET to discuss recent developments and financial results. Sabirnetug (ACU193) is a humanized monoclonal antibody targeting toxic soluble amyloid beta oligomers in Alzheimer’s disease. The company is focused on advancing sabirnetug in the ongoing Phase 2 clinical trial ALTITUDE-AD for early symptomatic Alzheimer’s disease following positive Phase 1 results.

Financially, Acumen Pharmaceuticals reported $231.5 million in cash, cash equivalents, and marketable securities as of Dec. 31, 2024, with increased R&D and G&A expenses compared to 2023. The company’s loss from operations in 2024 was $114.0 million, with a net loss of $102.3 million for the year. Cash is expected to support activities into the first half of 2027.



Read more at GlobeNewswire:: Acumen Pharmaceuticals Reports Financial Results for the